Abstract
Objective: To investigate the pathophysiology of Type 1 Narcolepsy.
Background: Type 1 narcolepsy (T1N) is caused by a hypocretin (HCRT, also called orexin) cell loss. Association with DQB1*06:02/DQA1*01:02 (DQ0602, 98% vs. 25%), T cell receptors (TCR) and other loci indicate autoimmunity. Onset is seasonal and associated with influenza-A, notably pandemic 2009H1N1 (pH1N1) infection and the pH1N1 vaccine Pandemrix. The strong HLA association and unique effects in TCRA and TCRB suggest that autoantigen presentation by DQ0602 to CD4+ T cell is crucial. We surveyed CD4+ T cell binding to autoantigens and flu antigens presented by DQ0602 in narcolepsy versus controls, identifying the immunological basis of narcolepsy.
Design/Methods: DQ0602 binding was tested for peptides overlapping RFX4, HCRT and flu HA, NA, PB1and NP sequences. Reactivity to ~100 tetramers was tested in 6 narcolepsy and 4 controls after expansion of cells in 10-day cultures. Higher tetramer-peptide specific CD4+ T cells was found with HCRT54–66-NH2, HCRT86–97-NH2 (HCRTNH2), pHA273–287 and NP17–31, further confirmed for HCRTNH2 and pHA273–287 in 77 T1N and 44 DQ0602 controls. Single cell TCR sequencing after FACS sorting was conducted and public TCR clones transfected into Jurkat76 cells to test for activation after peptide presentation by K562-DQ0602 or RM3-DQ0602 cells.
Results: Most commonly used public sequences CDR3β-TRBV4-2-CASSQETQGRNYGYTF, CDR3a-TRAV2-CAVETDSWGKLQF-TRAJ24 and TRAV26-1-CIVRSQGGSYIPTF-TRAJ6 were retrieved using both DQ0602-HCRTNH2 and DQ0602-pHA273–287 but not DQ0602-NP17–31 tetramers. Sharing of clones using TRAJ24 and TRBV4-2 was notable as these exact segments (~0.8% of repertoire) are modulated by rs1154155/rs1483979 and rs1008599, polymorphisms associated with T1N. Jurkat cells transfected with some clones were activated by HCRTNH2 and pHA273–287, suggesting molecular mimicry. As a control, NP17–31 involved different TCRs, notably TRAV8-6_TRAJ34 with TRBV7-9_TRBJ2-3 and was only activated by NP17–31.
Conclusions: Our results provide strong evidence for autoimmunity and molecular mimicry with flu antigens modulated by genetic components in the pathophysiology of T1N.
Disclosure: Dr. Luo has nothing to disclose. Dr. Ambati has nothing to disclose. Dr. Lin has nothing to disclose. Dr. Partinen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Has participated in advisory boards of AOP Orphan, Bioprojet, UCB, and Umecrine. Dr. Partinen has received research support from Has received research support for clinical trials for Bioprojet, Jazz Pharmaceuticals, MSD, and Umecrine. Dr. Ji has nothing to disclose. Dr. Maecker has nothing to disclose. Dr. Mignot has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr Mignot has consulted for Novo Nordisk and Reset Pharmaceuticals, and is on the speakers' bureau for Vox Media.. Dr. Mignot has received research support from Dr. Mignot has received research support from Jazz Pharmaceuticals, Merck, and Glaxo Smith Kline (GSK).
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.